Exact Sciences Corporation (NASDAQ:EXAS) currently has a “Sell” signals on Composite indicators by TrendSpotter. While the Short-Term Technical Indicators for the stock on 7-Day Average Directional Indicator shows “Sell” signal. 10 – 8 Day Moving Average Hilo Channel shows “Sell” signal. While 20-Day Moving Average VS Current Price shows “Sell” Signal.
Exact Sciences Corporation (NASDAQ:EXAS) gained 0.62 Percent and closed its previous trading session at $50.31. The stock traded with the average Volume of 2.26 Million at the end of last session.
Exact Sciences Corporation (NASDAQ:EXAS) has the Market Capitalization of 7.19 Billion. The Stock has its 52-week High of $71.60 and 52-Week Low of $36.10 and it touched its 52-week high on 06/18/18 and 52-Week Low on 08/11/17
The company reported its last earnings Actual EPS of $-0.3/share. While, the analyst predicted that the company could provide an EPS of $-0.32/share. Hence the difference between Predicted EPS and Actual EPS reported is $0.02/share which shows an Earnings Surprise of 6.3 Percent.
Sell side analysts plays vital role in buying and selling a stock where 1 analysts rated Exact Sciences Corporation (NASDAQ:EXAS) as Buy, 0 analysts given Outperform signal, 1 reported Hold, and 0 analysts rated the stock as Sell.
The stock’s current distance from 20-Day Simple Moving Average (SMA20) is -16.32% where SMA50 and SMA200 are -19.29% and -5.97% respectively.
The company shows its Return on Assets (ROA) value of -12.7%. The Return on Equity (ROE) value stands at -20.1%. While it’s Return on Investment (ROI) value is -46.3%.
Exact Sciences Corporation (NASDAQ:EXAS) currently has a Weekly Volatility of 2.61% percent while its Monthly Volatility is at 3.79% percent. While talking about Performance of the Stock, Exact Sciences Corporation currently has a Weekly performance of -2.56%, monthly performance percentage is -19.5 percent, Quarterly performance is -2.67 percent, 6 months performance shows a percent value of 12.9% and Yearly Performance is 35.06 percent.
EXACT Sciences Corporation uses applied genomics to develop effective, patient-friendly screening technologies for use in the detection of cancer. Certain of its technologies have been licensed to Laboratory Corporation of America Holdings for a stool-based DNA screening assay for colorectal cancer in the average-risk population. Colorectal cancer, which is the most deadly cancer among non-smokers, is generally curable if detected early. Despite the availability of colorectal cancer screening and diagnostic tests for more than twenty years, the rate of early detection of colorectal cancer remains low, and deaths from colorectal cancer remain high. EXACT Sciences believes its genomics-based technologies would help to enable detection of colorectal cancer so that more people can be effectively treated.